NEWS RELEASE
Merz Therapeutics Hosts Over 300 International Healthcare Professionals at its First Global “Merz Expert Connect Summit 2023”
Frankfurt, Germany, October 6, 2023 – Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, kicked off its first “Merz Expert Connect Summit” today. The event focuses on advanced treatment options for movement disorders, spasticity, and sialorrhea to better serve people living with these conditions. More than 300 international experts in rehabilitation medicine and neurology will attend the event in Berlin from 6–7 October. The schedule includes educational sessions and hands-on training, giving healthcare professionals of different backgrounds and levels of experience opportunities to connect, exchange experiences, gain theoretical knowledge, and hone their practical skills. “Bringing together experts, educating real-world clinicians about improvements in therapy and discussing a pathway to more patient-centered treatments is the most sustainable way to continue improving patient care,” explains Merz Therapeutics Chief Executive Officer, Stefan König.
The “Merz Expert Connect Summit” is the largest global stand-alone event of its scale in the company’s history. “We are proud to welcome guests from over 30 different nations here in Berlin and are looking forward to two days filled with opportunities for fruitful exchange and learning”, says Dr Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics.
The program of the “Merz Expert Connect Summit” features more than 27 lectures by international thought leaders on a variety of relevant topics. Among them are members of ToxNET, a network of 20 leading international experts and renowned key opinion leaders in movement disorders and neurology, who will hold a session introducing various tools for defining patient goals. In addition to theoretical knowledge, the Summit also seeks to address a very practical challenge that people living with spasticity, stroke, cerebral palsy, or sialorrhea face every day: the lack of physicians trained in the use of ultrasound to support targeted injection of botulinum toxin.
Educating physicians to benefit patients
“Currently, there is a lack of physicians trained in the use of botulinum toxin, so patients with cervical dystonia, spasticity, or sialorrhea struggle to receive proper treatment, have to travel far distances or wait long for their appointments. There is a critical need for education and exchange about treatment options,” Dr Stefan Albrecht explains. “This is a gap the event aims to fill. Offering best-in-class education is crucial to ensuring that the best possible care becomes available to more patients. But we also aim for fruitful exchange and networking, as well as getting further inspiration from the physicians’ thinking: What is really needed to bring better outcomes for more patients? Because changing for the better, looking for constant innovation – also in the training field – is what drives us at Merz Therapeutics,” adds Claudia Cramer, Head of Central Commercial Organization.
Looking to the future, Merz Therapeutics plans to continue to leverage its industry expertise while showcasing its commitment to research and development. “The ‘Merz Expert Connect’ is contributing greatly to this. We are proud of our recent successes in the movement disorders, spasticity, and sialorrhea markets, with several significant milestones achieved and promising development prospects outlined for the future. We remain dedicated to challenging the status quo with our innovative healthcare solutions,” Stefan König concludes.
About Merz Therapeutics
Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.
Please visit www.stage.merztherapeutics.com
About Merz
Merz Group is a global, diversified company with its headquarters in Frankfurt, Germany. Its commitment to innovation, long-term perspective, and focus on profitable growth depict the privately owned company that has been around for more than 110 years. Merz Group has the businesses Merz Aesthetics, Merz Therapeutics, Merz Lifecare, Merz Real Estate and Financial Investments. The company employs 3,969 people in 28 countries worldwide.
To learn more, please visit http://www.merz.com/
